Spyre Therapeutics (SYRE) Corporate presentation summary

Strategic focus and pipeline overview

• Developing next-generation therapies for immunology, targeting IBD and rheumatic diseases with both monotherapies and rational combinations designed for best-in-class efficacy and convenience.

• Programs include anti-TL1A, anti-a4β7, anti-IL-23, and combinations thereof, aiming for 2–4 doses per year after loading.

• Robust clinical pipeline with multiple Phase 2 trials in ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.

• Six Phase 2 proof-of-concept readouts expected in 2026 from two innovative trials (SKYLINE and SKYWAY).

• $1.2 billion pro forma cash as of March 31, 2026, with expected runway into 2H 2029.

Clinical and preclinical data highlights

• Next-generation antibodies (SPY001, SPY002, SPY003) show comparable or superior in vitro potency and clinical remission rates to first-generation molecules.

• YTE modification extends antibody half-life, enabling quarterly or twice-annual dosing.

• PK simulations support 2–4 doses per year for lead assets, with maintenance intervals of 3–6 months.

• Preclinical models demonstrate additive-to-superior efficacy for rational combinations in IBD and robust anti-TL1A activity in arthritis and skin disease models.

• SPY001 met its primary endpoint and exceeded expectations on key secondary endpoints in Phase 2 induction for UC, with a favorable safety profile.

Market opportunity and unmet need

• Significant unmet need in IBD (~2.4M US patients) and rheumatic diseases (>3M US patients), with current therapies limited by low remission rates, safety concerns, and inconvenient dosing.

• Global markets estimated at $40B for IBD and $30B for rheumatic diseases.

• Combination therapies have demonstrated additive or synergistic efficacy in clinical studies, supporting the rationale for Spyre’s approach.